Kura Oncology, Inc. (NASDAQ:KURA) Receives $28.00 Consensus Price Target from Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have received an average rating of “Moderate Buy” from the twelve analysts that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $28.00.

A number of brokerages have issued reports on KURA. Leerink Partners set a $20.00 price target on Kura Oncology and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Wedbush reiterated an “outperform” rating and set a $38.00 price objective (up from $36.00) on shares of Kura Oncology in a report on Friday, November 14th. UBS Group boosted their target price on shares of Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, November 14th. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research report on Friday, December 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a research note on Tuesday, January 13th.

Kura Oncology Stock Performance

Shares of KURA opened at $7.83 on Tuesday. Kura Oncology has a 1 year low of $5.41 and a 1 year high of $12.49. The company’s 50 day simple moving average is $9.75 and its 200 day simple moving average is $9.12. The company has a market capitalization of $681.37 million, a price-to-earnings ratio of -3.16 and a beta of 0.23. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12.

Insiders Place Their Bets

In related news, insider Mollie Leoni sold 15,485 shares of Kura Oncology stock in a transaction on Friday, November 14th. The stock was sold at an average price of $11.18, for a total value of $173,122.30. Following the transaction, the insider owned 225,454 shares in the company, valued at approximately $2,520,575.72. This trade represents a 6.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian T. Powl sold 8,887 shares of the company’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $11.18, for a total value of $99,356.66. Following the sale, the insider owned 139,689 shares of the company’s stock, valued at $1,561,723.02. This represents a 5.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 104,411 shares of company stock worth $1,035,994. Corporate insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KURA. IFP Advisors Inc increased its position in shares of Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after acquiring an additional 1,284 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Kura Oncology by 392.8% during the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after purchasing an additional 3,072 shares in the last quarter. Allworth Financial LP boosted its position in shares of Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after buying an additional 1,553 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after buying an additional 3,769 shares in the last quarter. Finally, Merit Financial Group LLC purchased a new stake in shares of Kura Oncology during the 3rd quarter valued at about $89,000.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.